secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001193125-26-062534
Event type: other
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara defers $9M milestone payment to HCRx to Jan 2028; issues 400K share warrant
--------------------------------------------------------------------------------

- HCRx agreed to extend $9.0M milestone payment due from June 30, 2026 to Jan 1, 2028.
- Atara issued warrant to purchase 400K shares at $0.0001/share, exercisable immediately, no expiration.
- CEO cites flexibility to address FDA Complete Response Letter (CRL) for tabelecleucel.
- Tabelecleucel is approved in Europe for EBV+ PTLD; working with FDA for US path.
- Warrant subject to 4.99% beneficial ownership limit; net number via cashless exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526062534/0001193125-26-062534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526062534/d105335d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-062534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer